|
Originally published In Press as doi:10.1074/jbc.M002134200 on April 14, 2000
J. Biol. Chem., Vol. 275, Issue 25, 18905-18912, June 23, 2000
Casein Kinase I Is Anchored on Axonemal Doublet Microtubules and
Regulates Flagellar Dynein Phosphorylation and Activity*
Pinfen
Yang and
Winfield S.
Sale
From the Department of Cell Biology, Emory University School of
Medicine, Atlanta, Georgia 30322
Received for publication, March 14, 2000, and in revised form, April 12, 2000
 |
ABSTRACT |
Flagellar dynein activity is regulated by
phosphorylation. One critical phosphoprotein substrate in
Chlamydomonas is the 138-kDa intermediate chain (IC138) of
the inner arm dyneins (Habermacher, G., and Sale, W. S. (1997)
J. Cell Biol. 136, 167-176). In this study, several
approaches were used to determine that casein kinase I (CKI) is
physically anchored in the flagellar axoneme and regulates IC138
phosphorylation and dynein activity. First, using a videomicroscopic motility assay, selective CKI inhibitors rescued dynein-driven microtubule sliding in axonemes isolated from paralyzed flagellar mutants lacking radial spokes. Rescue of dynein activity failed in
axonemes isolated from these mutant cells lacking IC138. Second, CKI
was unequivocally identified in salt extracts from isolated axonemes,
whereas casein kinase II was excluded from the flagellar compartment.
Third, Western blots indicate that within flagella, CKI is anchored
exclusively to the axoneme. Analysis of multiple Chlamydomonas motility mutants suggests that the axonemal
CKI is located on the outer doublet microtubules. Finally, CKI
inhibitors that rescued dynein activity blocked phosphorylation of
IC138. We propose that CKI is anchored on the outer doublet
microtubules in position to regulate flagellar dynein.
 |
INTRODUCTION |
The dynein ATPase is a family of molecular motors responsible for
diverse cellular functions including retrograde microtubule-based transport of organelles, assembly and function of the Golgi and mitotic
apparatus, and movement of cilia and flagella (1, 2). One of the
primary questions is how dynein activity is regulated. The focus of
this report is based on a series of studies revealing that the
flagellar central pair apparatus and radial spokes play a primary role
in regulation of flagellar dynein activity (3, 4). The regulatory
mechanism involves a structural network of axonemal kinases and
phosphatases that control phosphorylation of key subunits within the
inner arm dyneins (5-8). In particular, phosphorylation of a dynein
intermediate chain subunit,
IC138,1 correlates with
inhibition of flagellar dynein activity (7). This network of enzymes
along with the central pair apparatus, radial spokes, and the inner arm
dyneins operates to control flagellar waveform (9-17).
These conclusions are based on genetic analysis and in vitro
functional studies of flagella from Chlamydomonas
reinhardtii. For example, mutations that disrupt either the
central pair or the radial spokes result in flagellar paralysis (2, 3,
18). These paralyzed axonemes undergo dynein-driven microtubule sliding in vitro (19) but at greatly reduced rates of sliding when
compared with wild-type axonemes (20). Reconstitution and functional assays demonstrate that the radial spokes are required for wild-type dynein activity, and the velocity of dynein-driven microtubule sliding
is mediated by posttranslational modification of the inner dynein arms
(20). These results are consistent with other evidence indicating that
the central pair/radial spoke apparatus along with the dynein
regulatory complex controls dynein activity (14, 17, 21-26). The
challenge has been to define the biochemical signaling pathway and to
determine how this biochemistry can be altered by mechanical
interaction between the central pair structures, radial spoke
structures, and outer doublet microtubule components to control dynein activity.
Diverse experimental systems have revealed that ciliary and flagellar
motility is controlled by phosphorylation and that the protein kinases
and phosphatases responsible for regulation are anchored in the axoneme
(27-33). Thus, we postulate that phosphorylation regulates dynein
activity, and key kinases and phosphatases are anchored in the axoneme
near the dynein arms or in the central pair/radial spoke structures.
Consistent with this hypothesis, exogenously added protein kinase
inhibitors including PKI and the type II regulatory subunit of PKA
rescue wild-type microtubule sliding in isolated axonemes lacking
radial spokes (5). Moreover, in vitro reconstitution
experiments using double mutants lacking the radial spokes and selected
subsets of dynein arm structures reveal that one of the dyneins, inner
arm dynein I1, is required for rescue of dynein activity (7). The
simplest model is that PKA is anchored in the axoneme and controls
dynein activity and that the control mechanism requires changes in
phosphorylation of inner arm dynein I1. I1 is important for control of
flagellar waveform (12, 15), is functionally linked to the central pair apparatus/radial spoke system (14, 26), and contains the Tctex light
chain postulated to play a role in meiotic drive in t-haplotype mice
(34). We predict I1 contains the critical phosphoprotein subunit
required for control of dynein activity, and the 138-kDa intermediate
chain (IC138) of I1 is the only phosphoprotein in this complex (7).
Importantly, phosphorylation of IC138 correlates with inhibition of
dynein, and dephosphorylation of IC138 correlates with rescue of dynein activity.
It is now apparent that control of dynein is more complex than we
initially thought. PKA inhibitors such as PKI fail to block phosphorylation of IC138 at concentrations that rescue activity. Therefore, we conclude that additional axonemal kinases are involved in
the phosphorylation of IC138. Based on other studies (33, 35-37) and
preliminary pharmacological analysis, we postulate one of the casein
kinases (38) is anchored on doublet microtubules and directly
phosphorylates IC138. In this study, we show that CKI is located in the
axoneme, and inhibitors of CKI block phosphorylation of IC138 and
rescue dynein activity in paralyzed axonemes. We postulate that
axonemal CKI operates in concert with the axonemal PKA in a network to
control flagellar waveform through regulation of inner arm dynein
phosphorylation. The results provide an additional connection in the
physical circuitry of axonemal enzymes that control motility and offer
a new opportunity to define the mechanism for anchoring CKI to the
cytoskeleton (39).
 |
EXPERIMENTAL PROCEDURES |
Cell Strains and Growth Conditions--
The double mutants
pf28pf30 and pf14pf30 were described
previously (7, 40, 41). Dr. E. H. Harris (Duke University and Chlamydomonas Genetics Center) provided wild-type CC-124 and
other mutant cell strains. With the exception of pf14pf30,
all cells were grown in liquid-modified medium I (42) with aeration
over a 14:10 light/dark cycle. pf14pf30 cells were grown on
agar plates for 4 days prior to harvesting and suspension in liquid
medium (7).
Reagents and Kinase Inhibitors--
PKI, a peptide based on
residues 6-22 of the -isoform of the heat-stable inhibitor of PKA,
was synthesized and stored as described previously (5).
5,6-Dichloro-1- -D-ribofuranosylbenzimidazole (DRB,
Calbiochem) was stored as a 10 mM stock solution in ethanol and N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide
(CKI-7, Toronto Research Chemicals, North York, Canada) was stored as a
50 mM stock solution in Me2SO.
[ -32P]ATP, 3000 Ci/mmol, was obtained from NEN Life
Science Products. Peptide substrates for CKI, CKII, and PKA
(Leu-Arg-Arg-Ala-Ser-Leu-Gly, Kemptide) were purchased from Sigma.
Rabbit polyclonal antibodies include anti-Chlamydomonas
IC140 (43), anti-Chlamydomonas flagellar type 1 protein
phosphatase (PP1) (8), anti-chicken CKI (44), and
anti-Drosophila CKII catalytic and regulatory subunits (45). Except as noted, all other chemicals were from Sigma, and deionized water was used throughout.
Microtubule Sliding Assay--
Measurement of microtubule
sliding velocity was performed as described previously (5, 6, 46).
Flagella were isolated as described previously (41) and demembranated
with 0.5% Nonidet P-40 (Calbiochem) in motility buffer (10 mM Hepes, 5 mM MgSO4, 1 mM dithiothreitol, 0.5 mM EGTA, and 50 mM potassium acetate) except that all protease inhibitors
were left out of the motility buffer. The axoneme sample was then added
to a glass perfusion chamber and rinsed with motility buffer containing
1 mM ATP (and appropriate inhibitor or solvent control) to
remove nonadhering axonemes. Motility was initiated by perfusion of 1 mM ATP in motility buffer containing 1.5 µg/ml Nagarse.
Microtubule sliding was recorded by dark-field video and measured as
described previously (5, 6).
Flagellar Fractionation, Protein Isolation, and
Purification--
Flagella and axonemes were isolated as described
using the dibucaine procedure (41) and suspended in Buffer A (30 mM NaCl, 10 mM Hepes, pH 7.4, 5 mM
MgSO4, 1 mM dithiothreitol, 0.5 mM
EDTA, 0.1 mM phenylmethylsulfonyl fluoride, and 0.5 trypsin
inhibitory unit of aprotinin, pH 7.4) containing 0.5% Nonidet P-40.
Axonemes were sedimented by centrifugation and resuspended in Buffer A at ~2 mg/ml. Protein concentration was determined by the Coomassie Blue binding assay (Bio-Rad) using bovine serum albumin as a standard. For gel electrophoresis, protein samples were fixed in 5× sample buffer, unless stated otherwise, for SDS-PAGE or in-gel kinase assay.
For isolation of flagellar dyneins, axonemes were extracted at 8-10
mg/ml with 0.57 M NaCl in Buffer A. Following
centrifugation, the supernatant was dialyzed into Buffer A, and 0.6 ml
of the dialyzed extract was layered onto a 5-20% sucrose gradient in the same buffer and sedimented for 16 h at 36,000 rpm in a SW 41 rotor (Beckman) at 4 °C; 20 fractions were collected.
For isolation of axonemal CKI, axonemes were extracted at 5 mg/ml in
Buffer A containing 0.27 M NaCl. Following dialysis in the
appropriate buffer, the extract was fractionated either by velocity
sedimentation on sucrose gradients as described above or by DEAE ion
exchange chromatography. DEAE chromatography was carried out as
previously described (47) with modification. The 0.3 M NaCl
extract was dialyzed into DEAE buffer (20 mM Tris, pH 8, 2 mM EGTA, 2 mM EDTA, 5 mM
dithiothreitol, 10% glycerol), loaded onto a DEAE column (3-5 ml)
(Sigma), and washed with 30 ml of DEAE buffer, and 0.5-ml fractions
were collected at a flow rate of 0.3 ml/min from 15 ml of a linear
0.0-0.7 M NaCl gradient in DEAE buffer.
In some experiments, the peak CKI fractions from sucrose gradients
(made in Buffer A containing 30 mM NaCl) were fractionated by P-11 phosphocellulose chromatography as described previously (47).
Briefly, cellulose phosphate (Whatman, Kent, United Kingdom) was
precycled following the manufacturer's instruction and equilibrated in
P-11 buffer (25 mM phosphate buffer, pH 6.8, 10 mM -mercaptoethanol, 1 mM EDTA, 2 mM EGTA) containing 25 mM NaCl. The peak kinase
activity fractions from sucrose gradient sedimentation were pooled,
dialyzed in 25 mM NaCl in P-11 buffer, and loaded onto a
5-ml P-11 column. The column was washed in the same buffer, and
fractions were eluted with a 15-ml linear 0.025-1.25 M
NaCl gradient in P-11 buffer. The gradient was applied at 0.5 ml/min,
and about 0.8-ml fractions were collected.
Affinity purification of CKI was performed using -casein conjugated
to an agarose matrix (Sigma). -Casein-conjugated agarose beads (40 µl) were added to 200 µl of the DEAE CKI-containing fraction that
was diluted with an equal volume of 2× CK reaction buffer (50 mM Tris, pH 8, 0.1 mM EDTA, 0.2%
-mercaptoethanol, 7 mM magnesium acetate, 0.02% Brij
35, 20 mM NaCl, and 100 µM sodium
orthovanadate). The mixture was incubated at 4 °C overnight, and
after washing with CK buffer, the proteins sedimenting with the agarose
beads were fixed by suspension in 30 µl of 1× SDS-PAGE sample buffer.
In Vitro Phosphorylation of Axonemal Proteins--
For
phosphorylation, purified axonemes at 5 mg/ml were suspended in CK
reaction buffer in either the presence or absence of 50 µM CKI-7 or 200 nM PKI. 20-µl samples were
preincubated for 20-30 min at 30 °C, and [ -32P]ATP
was added to a final concentration of 40 µM (5000 cpm/pmol). The reaction was terminated at 2 min by adding
electrophoresis sample buffer. For sucrose gradient fractionation of
phosphorylated axonemal proteins, the reaction was scaled up to 500 µl of 10 mg/ml axoneme. Following phosphorylation, axonemes were
sedimented at 14,000 × g in a microcentrifuge and resuspended in
Buffer A containing 0.57 M NaCl and 10 µM
microcystin-LR to block phosphatase activity. Salt-extracted axonemes
were separated from the extract by sedimentation, and the extract was
dialyzed in Buffer A and subjected to velocity sedimentation on sucrose gradients.
For analysis of CKI autophosphorylation, each reaction contained 1× CK
reaction buffer, 14 µl of the DEAE fraction, and 100 µM
[ -32P]ATP (2000 cpm/pmol) in a total final volume of
20 µl. Before addition of ATP, DEAE fractions were preincubated in CK
buffer either in the presence or absence of 50 µM DRB for
20 min at 30 °C. Phosphorylation was initiated by the addition of 1 µl of [ -32P]ATP (3000 Ci/mmol) and terminated after
10 min by the addition of 5× sample buffer. In some cases, 1 µg of
-casein was included as a substrate.
Kinase Activity Assays--
Fractions were assessed for kinase
activity using specific peptide substrates. For casein kinase activity,
2-µl samples from gradient fractions or chromatography fractions were
added to a reaction mixture to a final volume of 20 µl containing CK
reaction buffer, 0.5 mg/ml CKI or CKII specific substrate, and 40 µM [ -32P]ATP (2000 cpm/pmol). For PKA
activity, 2-µl samples from fractions were added to the reaction
mixture to a final volume of 20 µl containing 25 mM MES,
pH 6, 5 mM MgCl2, 100 µM sodium
orthovanadate, 0.025% -mercaptoethanol, 2 µl of the fraction, 2.5 mg/ml Kemptide, and 150 µM [ -32P]ATP.
After 45 min at 30 °C, the reactions were terminated by adding 1 µl of 100% trichloroacetic acid. 10-µl samples from each reaction
were applied in duplicate to discs of P-81 filter paper (Whatman),
washed extensively with 75 mM phosphoric acid, and rinsed
with acetone. The radioactivity of the dried p-81 paper discs was
measured by scintillation counting.
In-gel Kinase Assay and Western Blot Analysis--
In-gel kinase
assays were carried out as described previously (48) with modification.
A stock solution of 10 mg/ml dephosphorylated casein (Sigma) in 1×
resolving buffer was added to a 9% acrylamide gel mixture to a final
concentration of 1 mg/ml casein. Following electrophoresis, the gel was
washed twice with ~250 ml of 20% isopropyl alcohol in Buffer B (50 mM HEPES, pH 7.4, 5 mM -mercaptoethanol) for
30 min each, and then washed with Buffer B alone for 30 min. For
renaturation of proteins, the gel was immersed in ~250 ml of 0.04%
Tween 20 in Buffer B at 4 °C overnight. The buffer was changed at
least six times during the overnight incubation period. The gel was
then incubated in 10 ml of Buffer C (50 mM Hepes, pH 7.4, 100 µM sodium orthovanadate, 10 mM
MnCl2, 5 mM -mercaptoethanol) at 30 °C
for 30 min. Phosphorylation was carried out by incubating the gel in
Buffer C with 7 µl of [ -32P]ATP at 30 °C for
3 h. To control for ATP binding, [ -32P]ATP was
used, and in some cases myelin basic protein was used in place of
casein. The reaction was terminated, and free nucleotides were rinsed
away by gentle shaking of the gel in ~250 ml of fixative solution (10 mM sodium pyrophosphate and 5% trichloroacetic acid) for
20 min with 5-7 solution changes. The gel was dried for phosphor imaging following Coomassie Blue staining.
For Western blots, samples separated with SDS-PAGE were transferred to
nitrocellulose membrane (Bio-Rad) and incubated with the first antibody
(affinity-purified anti-CKI-(183-249) at a 1:200 dilution, anti-PP1 at
a 1:5000 dilution, or anti-IC140 at a 1:5000 dilution). This was
followed by addition of horseradish peroxidase-conjugated secondary
antibody and ECL detection (8, 43).
 |
RESULTS |
Casein Kinase Inhibitors Rescue Dynein Activity in Paralyzed
Axonemes Lacking the Radial Spokes--
Radial spokes operate in part
to control axonemal kinases that otherwise would inhibit dynein
activity (5-8). We postulated that an axonemal casein kinase inhibits
dynein-driven microtubule sliding in paralyzed axonemes lacking the
radial spokes. The paralyzed, radial spoke mutant pf14 was
selected for our experiments because dynein activity is greatly reduced
in pf14 axonemes, and dynein activity can be rescued in
pf14 with kinase inhibitors (5). The prediction was that
using a videomicroscopic motility assay, inhibitors of casein kinases
would rescue wild-type dynein-driven microtubule sliding in
pf14 axonemes. We have shown that the key phosphatases
required to rescue dynein activity are also built into the structure
(5-8). As described previously, the velocity of microtubule sliding
(~7 µm/s) is greatly reduced in axonemes from pf14
mutants compared with microtubule sliding (~14-16 µm/s) in
axonemes from wild-type cells (Fig. 1).
Treatment of isolated pf14 axonemes with the casein kinase
inhibitors, DRB (100 µM) or CKI-7 (50 µM)
increased the velocity of microtubule sliding to ~13 µm/s (Fig. 1,
A and B), rescuing dynein-driven microtubule sliding. The effects of both DRB and CKI-7 were
dose-dependent, with half-maximal activity achieved with
~50 µM DRB and ~25 µM CKI-7.
Supplementing CKI-7 with PKI had no additional effect on microtubule
sliding compared with addition of CKI-7 alone. CKI-7 failed to rescue
wild-type sliding in axonemes from the double mutant
pf14pf30 (Fig. 1C), which lacks both the radial
spokes and inner arm dynein I1 (when compared with Ref. 7). These results strongly suggest that the isolated axoneme contains a casein
kinase that inhibits dynein activity in paralyzed mutants lacking
radial spokes and that the inner arm dynein I1 is required for rescue.
Based on the selectivity and Ki of CKI-7 for CKI,
when compared with CKII, PKA, or Ca2+/calmodulin kinase
(49, 50), the results indicate that CKI is responsible for inhibition
of dynein. We tested this hypothesis with direct biochemical
approaches.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 1.
Casein kinase inhibitors restore wild-type
dynein activity in axonemes from paralyzed mutant cells that lack
radial spokes. A videomicroscopic motility assay was used to
measure the velocity of dynein-driven microtubule sliding in isolated
axonemes. As described previously (20), dynein activity is greatly
reduced in axonemes lacking radial spokes (pf14). Incubation
of axonemes with either 100 µM DRB (A) or 50 µM CKI-7 (B) increased the velocity of
dynein-driven microtubule sliding, restoring wild-type activity
(p < 0.0005). In contrast, CKI-7 (or DRB) failed to
rescue dynein activity (p > 0.15) in a double mutant,
pf14pf30, lacking both the radial spokes and inner arm
dynein I1 (C). Bars indicate mean ± S.D.
|
|
Identification of a 39-kDa CKI from Purified
Axonemes--
Axonemes were isolated from wild-type cells and
extracted in a 0.3 M NaCl-containing buffer. The dialyzed
extract was then fractionated by one of three methods, and fractions
were analyzed for CKI, CKII, and PKA activity using specific peptide
substrates and an in-gel kinase assay (Fig.
2). Based on substrate specificity, CKI
activity (Fig. 2, top panels, open squares) was
most prominent in axonemal extracts. CKI was the first kinase to elute
from a DEAE ion exchange column (Fig. 2A, top
panel, fractions 9-11), and -casein was an equally
effective substrate for this kinase (data not shown). PKA and CKII
activities were also detectable but at much lower levels and in later
fractions. Using an in-gel kinase assay with casein embedded in the
gel, a prominent 39-kDa axonemal kinase was detected with peak activity
in fractions 9-11 (Fig. 2A, lower panel). This
same kinase activity was greatly reduced when myelin basic protein was
used as a substrate. The 39-kDa axonemal kinase co-fractionated with
CKI activity as an 8 S peak in sucrose gradients (Fig. 2B),
and P-11 phosphocellulose chromatography of the pooled sucrose gradient
fractions 15-19 also resulted in a peak of CKI activity that precisely
co-fractionated with the 39-kDa axonemal kinase (Fig. 2C).
In every case, either DRB or CKI-7 inhibited the phosphorylation of
CKI-peptide substrate or -casein (see below and Refs. 49 and 50).
DRB and CKI-7 had no effect on the phosphorylation of PKA peptide
substrate; when compared with CKI, CKII activity was significantly
lower with experimental variation. As discussed below, the variation in
CKII activity was caused by contamination from Chlamydomonas cell bodies.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 2.
A 39-kDa axonemal kinase, revealed by in-gel
kinase assay, co-purifies with axonemal CKI activity. An extract
from isolated axonemes (wild-type cells) was fractionated by either
DEAE chromatography (A) or by velocity sedimentation on
sucrose gradients (B). Peak kinase fractions from the
sucrose gradient were further fractionated by P-11 chromatography
(C). The top panels show relative kinase activity
in each fraction using specific peptide substrates. Empty
squares, CKI substrate; diamonds, CKII substrate;
solid triangles, Kemptide (PKA substrate). The bottom
panels show the corresponding fractions separated by SDS-PAGE and
analyzed by in-gel kinase assay and phosphor imaging using casein in
the acrylamide gel.
|
|
To further test whether the 39-kDa axonemal kinase is CKI, DEAE
fractions were analyzed for protein composition with Western blots and
-casein-agarose affinity precipitation. Silver-stained SDS-PAGE gels
revealed a prominent 39-kDa protein (Fig.
3A, left arrowhead)
that coincided with the CKI activity peak (Fig. 3A, fraction 15) and with the 39-kDa kinase determined by the
in-gel kinase assay (Fig. 3A, bottom). The
intensity of the protein stain indicates that the 39-kDa protein is a
prominent axonemal component. The component was specifically enriched
by affinity precipitation of -casein-agarose (Fig. 3A,
right, arrowhead). Moreover, an affinity-purified anti-CKI
antibody specifically recognized the 39-kDa protein in Western blots,
and immunoreactivity was also enriched by -casein-agarose affinity
precipitation (Fig. 3B). In contrast, Western blots failed
to detect the catalytic or regulatory subunit of CKII in flagella or
axonemes (see below).

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 3.
The 39-kDa axonemal kinase is CKI. A
salt extract from isolated axonemes (pf28pf30) was
fractionated by DEAE chromatography, and fractions were prepared for
SDS-PAGE and silver staining (A, top), in-gel
kinase assay (A, bottom), Western blots
(B), -casein affinity precipitation (A,
right and B, far right lane), and
in vitro kinase activity (C). The peak CKI
activity, fraction 15 (A, arrow), corresponded to a
prominent 39-kDa protein revealed by silver staining (A,
top, left arrowhead) and the 39-kDa
kinase revealed by in-gel kinase activity (A,
bottom). The 39-kDa axonemal protein was enriched by
-casein affinity (A, right
arrowhead). An anti-CKI antibody specifically bound to the
39-kDa protein, and the 39-kDa immunoreactive protein was enriched by
-casein affinity (B). C, addition of fraction
13 with [ -32P]ATP followed by SDS-PAGE and
PhosphorImager analysis revealed autophosphorylation of the 39-kDa
protein (C, left lane, arrowhead).
-Casein added to the same fraction also became phosphorylated
(C, middle lane), and DRB (or CKI-7) blocked
phosphorylation (C, right lane).
|
|
Fraction 13 from the DEAE ion exchange chromatography (Fig.
3A) was used in in vitro phosphorylation
experiments to further test for CKI activity (Fig. 3C).
Addition of 100 µM [ -32P]ATP to fraction
13 resulted in the apparent autophosphorylation of the 39-kDa protein
(Fig. 3C, lane 1, arrowhead), consistent with
previous studies that reveal autophosphorylation of CKI (51). The
-casein that was added to the fraction was heavily phosphorylated (Fig. 3C, lane 2), and DRB (25 µM) blocked
this phosphorylation (Fig. 3C, lane 3). Addition
of cAMP had no further effect on phosphorylation. We conclude that the
39-kDa axonemal kinase is CKI. The conclusion is based on the
following: (a) the elution position of the 39-kDa kinase
with DEAE chromatography compared with CKI studied in other systems
(47), (b) substrate specificity and potent, selective inhibition by DRB and CKI-7, (c) in-gel kinase assay,
(d) Western blot using a CKI-specific antibody, and
(e) -casein-agarose affinity precipitation.
Flagellar CKI Is Exclusively Anchored on the Axoneme--
Because
CKI inhibitors rescue dynein activity in isolated axonemes and the
39-kDa CKI is abundant in extracts from purified axonemes, we predict
that most or all of the flagellar CKI is anchored on the axonemal
microtubules. To test this hypothesis, Western blots were performed on
flagella, axonemes, and the Nonidet P-40 soluble membrane/matrix
fractions. Each sample was prepared from equal amounts of flagella.
Strikingly, nearly all of the flagella CKI co-purified with axonemes,
whereas little if any flagella CKI was found in the Nonidet P-40
membrane/matrix fraction (Fig. 4A,
top panel). The same distribution was detected using the in-gel
kinase assay. For comparison, as much as one-third of the flagellar
type 1 protein phosphatase (PP1) was present in the
detergent fraction (Fig. 4A, lower panel)
(8).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 4.
A, the 39-kDa flagellar CKI is anchored
in the axoneme (Axo.). Flagella were fractionated into
membrane/matrix and axonemal fractions, based on identical amount of
flagella (Fla.) and analyzed by Western blot. Most of the
CKI co-purified with axonemes, with little left in the
detergent-soluble fraction (compare the middle and
right lanes of the upper panel). In contrast, in
flagella, PP1, although greatly enriched in the axonemes, is also found
in the membrane/matrix fraction (lower panel and see Ref.
8). B, the 39-kDa CKI was not detectable in extracts
(ext.) from cell bodies (compare lanes in
left panel). In contrast, CKII was only detectable in
extracts from the cell body and lacking in flagella (right
panel). Each lane contained 50 µg of protein. C, the
axonemal 39-kDa CKI is located on outer doublet microtubules. The
in-gel kinase assay was used to determine whether mutant cells, which
fail to assemble specific axonemal structures, also fail to contain
CKI. Within a linear range of detection, axonemes lacking the dynein
regulatory complex (pf3), outer arm dynein and inner arm
dynein I1 (pf30pf28), radial spokes
(pf14), or central pair complex (pf18) contain
the same CKI activity as in wild-type axonemes. The same results were
obtained by Western blot analysis (data not shown). Thus, CKI is not
located in the central pair or radial spokes, leaving only the outer
doublet microtubules. Each lane contained 50 µg of
protein. WT, wild-type; CB, cell body.
|
|
We examined CKII distribution in Chlamydomonas using a CKII
polyclonal antibody recognizing both catalytic and regulatory subunits
of CKII. Although CKII was abundant in the cytoplasmic extract from the
cell body, it was excluded from the flagellar fraction (Fig. 4B,
right). In contrast, CKI, although enriched in flagella, was not
detected in the cell body extract (Fig. 4B, left). Thus,
based on subcellular localization, CKII did not directly phosphorylate
flagellar dynein nor did it directly contribute to the regulation of
flagellar motility.
These results demonstrate that the flagellar CKI is a stable component
of the 9 + 2 axonemal structure. To determine the location of axonemal
CKI, we used Western blots and the in-gel kinase assay to screen
flagella and axonemes isolated from mutant cells that fail to assemble
specific structures. This strategy has helped to define the composition
of structures such as the dynein arms, radial spokes, and central pair
and to determine the location of axonemal phosphatases (8). We
postulate that axonemal CKI is anchored to one or more distinct
structures. Predictably, failure to assemble the putative anchor
structure should result in failure of CKI to co-purify with axonemes.
However, using Western blot analysis and in-gel kinase assay, we did
not find a mutant strain that lacked CKI (Fig. 4C). In each
tested mutant, CKI co-purified with the axoneme. For example, in Fig.
4C an in-gel kinase assay revealed that equal activity of
the 39-kDa CKI in axonemes from wild-type or mutant cells failed to
assemble the dynein regulatory complex (pf3), outer and
inner arm dyneins (pf28pf30), radial spokes
(pf14), and central pair apparatus (pf18). The
same results were obtained using the anti-CKI antibody in Western blots
comparing proteins from both flagella and axonemes (data not shown).
Both assays, although not strictly quantitative, were performed within a linear range of detection using identical protein loads for each
sample. Thus, we conclude that CKI is not exclusively located in the
central pair apparatus, radial spoke, or dynein regulatory complex. The
simplest interpretation is that CKI is anchored to the outer doublet
microtubules in one or more positions to control dynein activity. The
simplest prediction is that CKI is anchored in position to directly
control dynein phosphorylation. To test this, we determined whether
CKI-7, at the same concentration used to rescue dynein activity, will
also block phosphorylation of dynein subunits.
CKI-7 Blocks Phosphorylation of IC138--
The foundation of this
project was to identify the axonemal kinase that directly controls
phosphorylation of IC138 and inhibits dynein activity. As described in
the Introduction, preliminary studies with inhibitors of PKA failed to
block phosphorylation of IC138. Based on the functional and biochemical
analysis described above, we tested whether the axonemal CKI is
involved in phosphorylation of IC138. Axonemes were isolated from
wild-type and pf14 cells and treated with either PKI or
CKI-7 prior to addition of 40 µM [ -32P]ATP. The ATP concentration selected was based on
kinetic studies of CKI and the evidence that the Km
for ATP was 5-25 µM (52). However, we found no effect by
the concentration of ATP over a range of 0.1-150 µM. A
number of axonemal proteins became labeled upon exposure to
[ -32P]ATP (Fig. 5,
left lane). Particularly prominent is a phosphoprotein with
a mass of about 138 kDa (Fig. 5, arrowhead). The same
138-kDa phosphoprotein was missing in axonemes from
pf28pf30, a mutant cell lacking inner arm dynein I1,
suggesting the 138-kDa protein is IC138 of I1 (data not shown) (see
below, Fig. 6). Addition of PKI fails to block phosphorylation of
proteins from either wild-type or pf14 axonemes (Fig. 5,
lanes 1 and 2). Similarly, selective inhibitors
of CKII, such as hypericin, had no effect on phosphorylation. In
contrast, 15-50 µM CKI-7 blocked phosphorylation of
several axonemal proteins (including the 138-kDa phosphoprotein) from
wild-type cells and greatly reduced phosphorylation of axonemal proteins from pf14 cells (Fig. 5). Addition of both PKI and
CKI-7 had no further affect on phosphorylation. For unknown reasons, phosphorylation was more pronounced, with higher background, in axonemes from pf14 compared with axonemes from wild-type
cells (Fig. 5).

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 5.
Several axonemal proteins, including a
138-kDa protein, are phosphorylated in isolated axonemes in
vitro. CKI-7 inhibited phosphorylation of a subset of
axonemal proteins including the 138-kDa protein. Isolated axonemes from
wild-type or pf14 cells were incubated with 200 nM PKI and 15 µM or 50 µM CKI-7
prior to addition of [ 32-P]ATP. Following a 5 min
incubation, samples were prepared for SDS-PAGE and phosphorimager
analysis. Prominent axonemal phosphoproteins include a 138-kDa protein
(arrowhead). PKI failed to block phosphate incorporation. In
contrast, CKI-7 blocked phosphorylation of a number of axonemal
proteins including the 138-kDa protein.
|
|
These results are consistent with the hypothesis that CKI plays a
central role in phosphorylation of several axonemal proteins including
a prominent phosphoprotein of ~138 kDa. It had been previously
demonstrated that phosphorylation of IC138 correlates with inhibition
of flagellar dynein activity (7). Thus, we postulated that the 138-kDa
phosphoprotein is IC138. To test this directly, axonemes from
pf14 were exposed to 40 µM
[ -32P]ATP in either the presence or absence of 50 µM CKI-7. The dynein complexes were extracted, dialyzed,
and fractionated by velocity sedimentation on sucrose gradients.
Proteins separated by 10% SDS-PAGE were revealed by Coomassie Blue
staining (Fig. 6A), and phosphorylation was evaluated by phosphor imaging (Fig. 6B).
As previously described (7, 15), a 138-kDa phosphoprotein in fractions
containing the I1 inner arm dynein complex was strongly labeled (Fig.
6, A and B, arrowhead, fraction
3 peak). In contrast, other subunits of I1, intermediate and light
chains of outer dynein arms, and tubulin did not become phosphorylated.
Addition of 50 µM CKI-7 blocked phosphorylation of
several proteins including IC138 (Fig. 6B). Phosphorylation
of a subset of other axonemal phosphoproteins was not affected (Fig.
6B, arrows). In mutants lacking I1, IC138 was absent (Fig.
6A, right panel, arrowhead), and no
phosphoprotein was present in the 20 S fraction from extracts derived
from the I1 mutants (Fig. 6B, right,
arrowhead).

View larger version (89K):
[in this window]
[in a new window]
|
Fig. 6.
The 138-kDa axonemal phosphoprotein is salt
extractable, co-purifies with IC138 of inner arm I1, and CKI-7 blocks
phosphorylation of 138 kDa in isolated axonemes. Isolated
axonemes, either plus or minus CKI-7, were phosphorylated, as described
in Fig. 5 and then extracted in 0.6 M NaCl, dialyzed, and
fractionated by velocity sedimentation on sucrose gradients. Fractions
were analyzed by SDS-PAGE and Coomassie Blue staining to identify
dynein subunits (A) and phosphorimager analysis to identify
phosphoproteins (B). Fractions containing outer arm dynein
(Od), or inner arm dynein I1 (I1) were identified
based on sedimentation and intermediate chain molecular weight (outer
arm dynein, IC78 and IC69; inner arm dynein,
IC140, IC138, and IC97 (A, left
panel). IC138 is missing in a mutant (pf28pf30)
that fails to assemble inner arm dynein I1 (A, right
panel, arrowhead). As described before (7), IC138 is
the only phosphoprotein among I1 subunits (B, left
arrowhead). CKI-7 blocked phosphorylation of IC138 (B, right
arrowhead) under conditions that failed to block phosphorylation
of several other axonemal phosphoproteins (B, arrows). As
expected, the 138-kDa phosphoprotein is missing in a mutant lacking I1
(B, right panel, arrowhead).
|
|
To further confirm that the 138-kDa phosphoprotein was IC138, gradient
fractions were separated on a 5% gel and were analyzed for protein
content by Amido-Black staining and for phosphorylation by phosphor
imaging and Western blot analysis using an antibody against IC140 (43).
As previously described, IC140 and IC138 were resolved and detected as
distinctive proteins (Fig. 7A, left panel). IC140 was confirmed by Western blot analysis (Fig.
7A, far right lane), and IC138 migrated slightly
faster and coincident with the 32P-labeled band (Fig.
7A, arrowhead). CKI-7 inhibited the
phosphorylation of IC138 (Fig. 7B). Based on scintillation
counting of the excised IC138 band, as well as quantitation by phosphor
imaging, CKI-7 treatment resulted in 80% inhibition of 32P
incorporation into IC138.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 7.
The 138-kDa axonemal phosphoprotein is IC138,
and CKI-7 blocks phosphorylation of IC138 in axonemes. To further
confirm that the 138-kDa protein is IC138, the proteins, and
phosphoproteins, from I1-containing gradient fractions were separated
on 5% gels and analyzed by Western blots and phosphorimaging.
Amido-black staining of fractions reveals a clear separation between
IC140 and IC138 (A, left panel). The identity of IC140 is
confirmed by Western blot analysis (A, right panel), and
phosphorimage analysis revealed IC138 is the phosphoprotein (A,
middle panel). Phosphorylation of IC138 was reduced by 80% in
axonemes incubated with CKI-7 (B).
|
|
 |
DISCUSSION |
In this study, we have addressed the hypothesis that the key
kinases responsible for regulation of flagellar dyneins are anchored in
the axonemal framework. We have identified an axonemal CKI and
demonstrated that CKI controls phosphorylation of IC138 and dynein
activity. Specifically we have shown the following. (a) Selective CKI inhibitors restore dynein activity in isolated axonemes lacking radial spokes, (b) inner arm dynein I1 is required
for rescue of dynein activity, (c) the 39-kDa axonemal
kinase is CKI, (d) CKI is a relatively abundant axonemal
protein likely located on outer doublet microtubules, and
(e) CKI inhibitors that were shown to rescue dynein activity
block phosphorylation of IC138.
The simplest interpretation is that CKI is anchored on outer doublet
microtubules near the base of radial spoke 1 and near the base of I1,
in position to control phosphorylation of IC138. Genetic and in
vitro functional assays have demonstrated that I1, through a
network of structures including the radial spokes, operates in part to
control flagellar waveform (Refs. 10-15 and 26). Based on results from
the current study, we postulate CKI is a key enzyme in this network
that is designed to control flagellar waveform.
The 39-kDa Axonemal Kinase Is CKI--
The identification of CKI
in the axoneme is based on a number of results. Using isolated and
purified axonemes as a starting point, in-gel kinase assays revealed a
39-kDa band. In salt extracts from the axonemes, the 39-kDa band
exclusively co-purified with CKI activity. This conclusion is based
upon fractionation of the extracts by a number of approaches: kinase
activity using selective substrates, inhibition of activity with DRB
and CKI-7 (49, 50), molecular mass of the catalytic protein, Western
blot analysis, and -casein affinity precipitation (Figs. 2 and 3).
Thus, the evidence is compelling that the 39-kDa axonemal kinase is CKI (38, 39). Using the Advanced Blast search algorithm of a
Chlamydomonas expressed sequence tag data base, we
identified the two Chlamydomonas CKI sequences that are the
most homologous to the N terminus and C terminus of mammalian CKI (39, 53). The mammalian CKI is predominantly expressed in rat
testis (53), suggesting that this homologue may be targeted to
flagella. Moreover, the putative Chlamydomonas sequence
predicts a 38.5-kDa protein, a size that matches the axonemal CKI. The
sequence predicts a very basic protein (pI of 9.3), a feature that may
play a role in CKI binding to the axoneme (see below) and may explain
why axonemal CKI is extractable at a relatively low salt concentration.
Peptide sequencing of the axonemal kinase and cloning will further test these ideas.
CKII activity is also present in some axonemal extracts; however, it is
variable between axonemal preparations, and the activity is very low in
the extracts (Fig. 2). More likely, the CKII activity found in the
axonemal extracts results from contamination by cell bodies. Consistent
with this conclusion, Western blots revealed that CKII, although
present in Chlamydomonas cells, is not found in isolated
flagella or axonemes (Fig. 4B). Thus, in
Chlamydomonas CKII appears to be excluded from flagella.
This is an important observation, indicating that CKII does not
directly control flagellar motility in Chlamydomonas, and
the cell has a mechanism to control protein entry into the flagellum.
CKI Is Targeted and Anchored to Axonemal Microtubules--
Nearly
all of the flagellar CKI co-purifies with isolated axonemes and is
excluded from the detergent-soluble, membrane/matrix fraction (Fig.
4A). The simplest conclusion is that CKI is targeted and
anchored to the axonemal microtubules. Alternatively, CKI may
coincidentally co-purify with axonemes. However, this seems most
unlikely because we have found no condition that leads to precipitation
of CKI, and CKI is active both on the axoneme and in axonemal extracts.
Thus, CKI appears to be specifically and exclusively attached to the
axoneme. This observation is consistent with models indicating that CKI
isoforms are physically positioned in cells to selectively interact
with and phosphorylate precisely defined substrates (39). For example,
CKI is targeted and anchored in the mitotic spindle, nuclear
structures, and membrane domains (54-57). One of the challenges is to
define the CKI anchor mechanisms. The Chlamydomonas axoneme
offers a new opportunity to define the interacting proteins that anchor
and regulate CKI in cells.
Within the axoneme, we postulate CKI is anchored to the outer doublet
microtubules, possibly in a position to affect inner arm I1
phosphorylation. This model is founded on the analysis of mutants that
indicate that CKI is not associated with the central pair or radial
spoke structures. The only structure remaining is the outer doublet
microtubules. Use of Chlamydomonas mutants has resulted in
successful localization of the dyneins (2, 18), central pair components
(3, 58), radial spokes (59), and the phosphatases PP1 and PP2A in the
axoneme (8). A prediction of the model is that CKI is a relatively
abundant axonemal component. Although we have not yet been able to
precisely define the stoichiometry of CKI in the axoneme, based on
Coomassie Blue staining of DEAE fractions, the 39-kDa CKI is comparable
in amount to axonemal proteins of similar size found in individual
inner arm dyneins (data not shown). Thus, the axoneme may contain
sufficient CKI so that it is present on each doublet microtubule and
anchored in each 96-nm repeat. This is precisely the position required for CKI to directly interact with and phosphorylate IC138.
Phosphorylation of IC138 and Control of Flagellar
Motility--
The most unique and important contribution of this study
is the discovery that CKI controls flagellar dynein activity and that
the mechanism for control involves phosphorylation of IC138 of the
inner arm dynein I1. These conclusions are founded first on definitive
pharmacological analysis of dynein function using direct,
videomicroscopic motility assays. These assays have previously revealed
that flagellar dynein is controlled by phosphorylation involving
axonemal kinases and phosphatases and is controlled by alteration in
phosphorylation of IC138 (5-8, 15). As illustrated in Fig. 1, CKI
inhibitors potently restore dynein activity, and rescue of dynein
activity requires IC138. The simplest model is that CKI operates
directly to phosphorylate IC138. Moreover, we postulate that an
axonemal PP2A operates to dephosphorylate IC138 (8). Consistent with
this model is the localization of both CKI and PP2A on the outer
doublet microtubules and the relatively selective inhibition of
phosphorylation of IC138 by CKI inhibitors (Figs. 6 and 7).
Alternatively, CKI may operate indirectly or synergistically with the
axonemal PKA. For example, glycogen synthase becomes a substrate for
CKI following phosphorylation of key residues by PKA (60-62). We have
discovered that radial spoke protein 3, located at the base of the
spoke, is an A kinase anchor protein, AKAP (63). Thus, PKA may also be
anchored in position to directly affect phosphorylation of IC138.
Although PKI fails to block phosphorylation of IC138, our methods may
not be sensitive enough to detect phosphorylation by PKA. More
definitive tests of these models will require an understanding of IC138
structure and interaction among CKI, PKA, and IC138.
Phosphorylation of I1 correlates with inhibition of dynein activity;
however, this observation alone does not explain the role of I1 and CKI
in flagellar motility. Based on phenotypic analysis of motility in
mutants lacking I1, it appears that I1 and phosphorylation of IC138
play a role in control of flagellar waveform (12, 15). Moreover,
genetic analysis has revealed a functional linkage between the central
pair/radial spoke structures and control of waveform (14, 21-26).
Although we do not yet know how alteration in dynein activity can
result in changes in waveform, part of the answer is that the central
pair/radial spoke system alters dynein activity via changes in
phosphorylation. The network of kinases and/or phosphatases must be
regulated by a mechanical interaction between the central pair
structure, radial spokes, and outer doublet microtubules. The challenge
is to develop approaches to test the idea that the activity of axonemal
enzymes such as CKI or PKA can be controlled by physical strain between
axonemal structures.
 |
ACKNOWLEDGEMENTS |
We are grateful to Drs. Z. Fu and G. S. Bennett, University of Florida, and C. V. C. Glover, University of
Georgia, for generously providing antibodies to casein kinases. We are
thankful to our colleagues, Drs. Rip Finst, Criss Hartzell, Harish
Joshi, Lynne Quarmby, and Barry Shur for helpful comments.
 |
FOOTNOTES |
*
This work was supported by the March of Dimes Birth Defects
Foundation and National Institutes of Health Grants GM51173 and GM17666.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Cell Biology,
Emory University School of Medicine, 1648 Pierce Dr., Atlanta, GA
30322. Tel.: 404-727-6265; Fax: 404-727-6256; E-mail:
win@cellbio.emory.edu.
Published, JBC Papers in Press, April 14, 2000, DOI 10.1074/jbc.M002134200
 |
ABBREVIATIONS |
The abbreviations used are:
IC138, the 138-kDa
intermediate chain of flagellar inner arm dynein I1;
PKA, protein
kinase A;
PKI, peptide inhibitor of PKA;
DRB, 5,6-dichloro-1- -D-ribofuranosylbenzimidazole;
CK, casein
kinase;
MES, 4-morpholineethanesulfonic acid;
PAGE, polyacrylamide gel
electrophoresis;
PP1, flagellar type 1 protein phosphatase;
CKI-7, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide.
 |
REFERENCES |
| 1.
|
Karki, S.,
and Holzbaur, E. L. F.
(1999)
Curr. Opin. Cell Biol.
11,
45-53
|
| 2.
|
Porter, M. E.
(1996)
Curr. Opin. Cell Biol.
8,
10-17
|
| 3.
|
Smith, E. F.,
and Lefebvre, P. A.
(1997)
Cell Motil. Cytoskeleton
38,
1-8
|
| 4.
|
Mitchell, D.
(2000)
J. Phycol.
36,
261-273
|
| 5.
|
Howard, D.,
Habermacher, G.,
Glass, D.,
Smith, E. F.,
and Sale, W. S.
(1994)
J. Cell Biol.
127,
1683-1692
|
| 6.
|
Habermacher, G.,
and Sale, W. S.
(1996)
J. Cell Sci.
109,
1899-1907
|
| 7.
|
Habermacher, G.,
and Sale, W. S.
(1997)
J. Cell Biol.
136,
167-176
|
| 8.
|
Yang, P.,
Fox, L.,
Colbran, R. J.,
and Sale, W. S.
(2000)
J. Cell Sci.
113,
91-102
|
| 9.
|
Warner, F. D.,
and Satir, P.
(1974)
J. Cell Biol.
63,
35-63
|
| 10.
|
Brokaw, C. J.,
Luck, D. J. L.,
and Huang, B.
(1982)
J. Cell Biol.
92,
722-732
|
| 11.
|
Brokaw, C. J.,
and Luck, D. J. L.
(1985)
Cell Motility
5,
195-208
|
| 12.
|
Brokaw, C. J.,
and Kamiya, R.
(1987)
Cell Motil. Cytoskeleton
8,
68-75
|
| 13.
|
Hosokawa, Y.,
and Miki-Noumura, T.
(1987)
J. Cell Biol.
105,
1297-1301
|
| 14.
|
Porter, M. E.,
Power, J.,
and Dutcher, S. K.
(1992)
J. Cell Biol.
118,
1163-1176
|
| 15.
|
King, S. J.,
and Dutcher, S. K.
(1997)
J. Cell Biol.
136,
177-191
|
| 16.
|
Omoto, C.,
Gibbons, I. R.,
Kamiya, R.,
Shingyoji, C.,
Takahashi, K.,
and Witman, G. B.
(1999)
Mol. Biol. Cell
10,
1-4
|
| 17.
|
Yoshimura, M.,
and Shingyoji, C.
(1999)
Cell Struct. Funct.
24,
43-54
|
| 18.
|
Dutcher, S. K.
(1995)
Trends Genet.
11,
398-404
|
| 19.
|
Witman, G. B.,
Plummer, J.,
and Sander, G.
(1978)
J. Cell Biol.
76,
729-747
|
| 20.
|
Smith, E. F.,
and Sale, W. S.
(1992)
Science
257,
1557-1559
|
| 21.
|
Huang, B.,
Ramanis, Z.,
and Luck, D. J. L.
(1982)
Cell
28,
115-124
|
| 22.
|
Piperno, G.,
Mead, K.,
and Shestak, W.
(1992)
J. Cell Biol.
118,
1455-1463
|
| 23.
|
Piperno, G.,
Mead, K.,
LeDizet, M.,
and Moscatelli, A.
(1994)
J. Cell Biol.
125,
1109-1117
|
| 24.
|
Porter, M. E.,
Knott, J.,
Gardner, L.,
Mitchell, D.,
and Dutcher, S. K.
(1994)
J. Cell Biol.
126,
1495-1507
|
| 25.
|
Gardner, L. C.,
O'Toole, E.,
Perrone, C. A.,
Giddings, T.,
and Porter, M. E.
(1994)
J. Cell Biol.
127,
1311-1325
|
| 26.
|
Myster, S.,
Knott, J.,
Wysoki, K. M.,
O'Toole, E.,
and Porter, M. E.
(1999)
J. Cell Biol.
146,
801-818
|
| 27.
|
Brokaw, C. J.
(1987)
J. Cell. Biochem.
35,
175-184
|
| 28.
|
Hasagawa, E.,
Hayashi, H.,
Asukura, S.,
and Kamiya, R.
(1987)
Cell Motil. Cytoskeleton
8,
302-311
|
| 29.
|
Hamasaki, T.,
Murtaugh, T.,
Satir, B.,
and Satir, P.
(1989)
Cell Motil. Cytoskeleton
12,
1-11
|
| 30.
|
San Agustin, J. T.,
and Witman, G. B.
(1994)
Cell Motil. Cytoskeleton
27,
206-218
|
| 31.
|
San Agustin, J. T.,
Leszyk, J.,
Nuwaysir, L.,
and Witman, G. B.
(1998)
J. Biol. Chem.
273,
24874-24993
|
| 32.
|
Walczak, C. E.,
and Nelson, D. L.
(1994)
Cell Motil. Cytoskeleton
27,
101-107
|
| 33.
|
Chaudhry, P.,
Creagh, S., Yu, N.,
and Brokaw, C. J.
(1995)
Cell Motil. Cytoskeleton
32,
65-79
|
| 34.
|
Harrison, A.,
Olds-Clarke, P.,
and King, S. M.
(1998)
J. Cell Biol.
140,
1137-1147
|
| 35.
|
Walczak, C. E.,
Anderson, R. A.,
and Nelson, D. L.
(1993)
Biochem. J.
296,
729-735
|
| 36.
|
Karki, S.,
Tokito, M. K.,
and Holzbaur, E. L. F.
(1997)
J. Biol. Chem.
272,
5887-5891
|
| 37.
|
King, S. M.,
and Witman, G. B.
(1994)
J. Biol. Chem.
269,
5452-5457
|
| 38.
|
Tuazon, P. T.,
and Traugh, J. A.
(1991)
Adv. Second Messenger Phosphoprotein Res.
23,
123-164
|
| 39.
|
Gross, S. D.,
and Anderson, R. A.
(1998)
Cell. Signalling
10,
699-711
|
| 40.
|
Piperno, G.,
Ramanis, Z.,
Smith, E. F.,
and Sale, W. S.
(1990)
J. Cell Biol.
110,
379-389
|
| 41.
|
Smith, E. F.,
and Sale, W. S.
(1992)
J. Cell Biol.
117,
573-581
|
| 42.
|
Witman, G. B.
(1986)
Methods Enzymol.
134,
280-290
|
| 43.
|
Yang, P.,
and Sale, W. S.
(1998)
Mol. Biol. Cell
9,
3335-3349
|
| 44.
|
Fu, Z.,
Green, C. L.,
and Bennett, G. S.
(1999)
J. Neurochem.
73,
830-838
|
| 45.
|
Dahmus, G. K.,
Glover, C. V.,
Brutlag, D. L.,
and Dahmus, M. E.
(1984)
J. Biol. Chem.
259,
9001-9006
|
| 46.
|
Okagaki, T.,
and Kamiya, R.
(1986)
J. Cell Biol.
103,
1895-1902
|
| 47.
|
Hathaway, G. M.,
and Traugh, J. A.
(1983)
Methods Enzymol.
99,
308-331
|
| 48.
|
Kameshita, I.,
and Fujisawa, H.
(1989)
Anal. Biochem.
183,
139-143
|
| 49.
|
Chijiwa, T.,
Hagiwara, M.,
and Hidaka, H.
(1989)
J. Biol. Chem.
264,
4924-4927
|
| 50.
|
Shugar, D.
(1994)
Cell. Mol. Biol. Res.
40,
411-419
|
| 51.
|
Hathaway, G. M.,
and Traugh, J. A.
(1979)
J. Biol. Chem.
254,
762-768
|
| 52.
|
Dobrowolska, G.,
Muszynska, G.,
and Shugar, D.
(1991)
Biochim. Biophys. Acta
1080,
221-226
|
| 53.
|
Graves, P. R.,
Haas, D. W.,
Hagedorn, C.,
DePaoli-Roach, A. A.,
and Roach, P. J.
(1993)
J. Biol. Chem.
268,
6394-6401
|
| 54.
|
Brockman, J. L.,
Gross, S. D.,
Sussman, M. R.,
and Anderson, R. A.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
9454-9458
|
| 55.
|
Kuret, J.,
Johnson, G. S.,
Cha, D.,
Christenson, E. R.,
DeMaggio, A. J.,
and Hoekstra, M. F.
(1997)
J. Neurochem.
69,
2506-2515
|
| 56.
|
Gross, S. D.,
Simerly, C.,
Schatten, G.,
and Anderson, R. A.
(1997)
J. Cell Sci.
110,
3083-3090
|
| 57.
|
Gross, S. D.,
Loijens, J. C.,
and Anderson, R. A.
(1999)
J. Cell Sci.
112,
2647-2656
|
| 58.
|
Mitchell, D.,
and Sale, W. S.
(1999)
J. Cell Biol.
144,
293-304
|
| 59.
|
Huang, B.,
Piperno, G.,
Ramanis, Z.,
and Luck, D. J. L.
(1981)
J. Cell Biol.
88,
80-88
|
| 60.
|
Flotow, H.,
and Roach, P. J.
(1989)
J. Biol. Chem.
264,
9126-9128
|
| 61.
|
Flotow, H.,
Graves, P. R.,
Wang, A.,
Fiol, C. J.,
Roeske, R. W.,
and Roach, P. J.
(1990)
J. Biol. Chem.
265,
14264-14269
|
| 62.
|
Roach, P. J.
(1991)
J. Biol. Chem.
266,
14139-14142
|
| 63.
|
Roush, A. M.,
and Sale, W. S.
(1999)
Mol. Biol. Cell
10,
388a (abstr.)
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Boesger, V. Wagner, W. Weisheit, and M. Mittag
Analysis of Flagellar Phosphoproteins from Chlamydomonas reinhardtii
Eukaryot. Cell,
July 1, 2009;
8(7):
922 - 932.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wirschell, C. Yang, P. Yang, L. Fox, H.-a. Yanagisawa, R. Kamiya, G. B. Witman, M. E. Porter, and W. S. Sale
IC97 Is a Novel Intermediate Chain of I1 Dynein That Interacts with Tubulin and Regulates Interdoublet Sliding
Mol. Biol. Cell,
July 1, 2009;
20(13):
3044 - 3054.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bower, K. VanderWaal, E. O'Toole, L. Fox, C. Perrone, J. Mueller, M. Wirschell, R. Kamiya, W. S. Sale, and M. E. Porter
IC138 Defines a Subdomain at the Base of the I1 Dynein That Regulates Microtubule Sliding and Flagellar Motility
Mol. Biol. Cell,
July 1, 2009;
20(13):
3055 - 3063.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. E. Dymek and E. F. Smith
A conserved CaM- and radial spoke associated complex mediates regulation of flagellar dynein activity
J. Cell Biol.,
November 5, 2007;
179(3):
515 - 526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schmidt, G. Gessner, M. Luff, I. Heiland, V. Wagner, M. Kaminski, S. Geimer, N. Eitzinger, T. Reissenweber, O. Voytsekh, et al.
Proteomic Analysis of the Eyespot of Chlamydomonas reinhardtii Provides Novel Insights into Its Components and Tactic Movements
PLANT CELL,
August 1, 2006;
18(8):
1908 - 1930.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Gaillard, L. A. Fox, J. M. Rhea, B. Craige, and W. S. Sale
Disruption of the A-Kinase Anchoring Domain in Flagellar Radial Spoke Protein 3 Results in Unregulated Axonemal cAMP-dependent Protein Kinase Activity and Abnormal Flagellar Motility
Mol. Biol. Cell,
June 1, 2006;
17(6):
2626 - 2635.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Wagner, G. Gessner, I. Heiland, M. Kaminski, S. Hawat, K. Scheffler, and M. Mittag
Analysis of the Phosphoproteome of Chlamydomonas reinhardtii Provides New Insights into Various Cellular Pathways
Eukaryot. Cell,
March 1, 2006;
5(3):
457 - 468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Yang and P. Yang
The Flagellar Motility of Chlamydomonas pf25 Mutant Lacking an AKAP-binding Protein Is Overtly Sensitive to Medium Conditions
Mol. Biol. Cell,
January 1, 2006;
17(1):
227 - 238.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. White, S. Aghigh, I. Magder, J. Cosson, P. Huitorel, and C. Gagnon
Two Anti-radial Spoke Monoclonal Antibodies Inhibit Chlamydomonas Axonemal Motility by Different Mechanisms
J. Biol. Chem.,
April 15, 2005;
280(15):
14803 - 14810.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. W. Hendrickson, C. A. Perrone, P. Griffin, K. Wuichet, J. Mueller, P. Yang, M. E. Porter, and W. S. Sale
IC138 Is a WD-Repeat Dynein Intermediate Chain Required for Light Chain Assembly and Regulation of Flagellar Bending
Mol. Biol. Cell,
December 1, 2004;
15(12):
5431 - 5442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. X. Chuong, A. G. Good, G. J. Taylor, M. C. Freeman, G. B. G. Moorhead, and D. G. Muench
Large-scale Identification of Tubulin-binding Proteins Provides Insight on Subcellular Trafficking, Metabolic Channeling, and Signaling in Plant Cells
Mol. Cell. Proteomics,
October 1, 2004;
3(10):
970 - 983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. DiBella, M. Sakato, R. S. Patel-King, G. J. Pazour, and S. M. King
The LC7 Light Chains of Chlamydomonas Flagellar Dyneins Interact with Components Required for Both Motor Assembly and Regulation
Mol. Biol. Cell,
October 1, 2004;
15(10):
4633 - 4646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Yang, C. Yang, and W. S. Sale
Flagellar Radial Spoke Protein 2 Is a Calmodulin Binding Protein Required for Motility in Chlamydomonas reinhardtii
Eukaryot. Cell,
February 1, 2004;
3(1):
72 - 81.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Rupp and M. E. Porter
A subunit of the dynein regulatory complex in Chlamydomonas is a homologue of a growth arrest-specific gene product
J. Cell Biol.,
July 7, 2003;
162(1):
47 - 57.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Perrone, D. Tritschler, P. Taulman, R. Bower, B. K. Yoder, and M. E. Porter
A Novel Dynein Light Intermediate Chain Colocalizes with the Retrograde Motor for Intraflagellar Transport at Sites of Axoneme Assembly in Chlamydomonas and Mammalian Cells
Mol. Biol. Cell,
May 1, 2003;
14(5):
2041 - 2056.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Wargo and E. F. Smith
Asymmetry of the central apparatus defines the location of active microtubule sliding in Chlamydomonas flagella
PNAS,
January 7, 2003;
100(1):
137 - 142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. F. Smith
Regulation of Flagellar Dynein by Calcium and a Role for an Axonemal Calmodulin and Calmodulin-dependent Kinase
Mol. Biol. Cell,
September 1, 2002;
13(9):
3303 - 3313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Yang, D. R. Diener, J. L. Rosenbaum, and W. S. Sale
Localization of Calmodulin and Dynein Light Chain LC8 in Flagellar Radial Spokes
J. Cell Biol.,
June 11, 2001;
153(6):
1315 - 1326.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Rupp, E. O'Toole, and M. E. Porter
The Chlamydomonas PF6 Locus Encodes a Large Alanine/Proline-Rich Polypeptide That Is Required for Assembly of a Central Pair Projection and Regulates Flagellar Motility
Mol. Biol. Cell,
March 1, 2001;
12(3):
739 - 751.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. E. Porter and W. S. Sale
The 9 + 2 Axoneme Anchors Multiple Inner Arm Dyneins and a Network of Kinases and Phosphatases that Control Motility
J. Cell Biol.,
November 20, 2000;
151(5):
F37 - F42.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Abel, B. J. Davids, L. D. Robles, C. E. Loflin, F. D. Gillin, and R. Chakrabarti
Possible Roles of Protein Kinase A in Cell Motility and Excystation of the Early Diverging Eukaryote Giardia lamblia
J. Biol. Chem.,
March 23, 2001;
276(13):
10320 - 10329.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|